Clinical trial
Empagliflozin Versus Vildagliptin in CAD Patients With T2DM
NCT06313008
Study timeline
Study start (actual)2023-08-10Date precision: day
Registry last updated2024-11-29
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Coronary Artery Diseaseunresolved
Type 2 Diabetesunresolved
Interventions
Empagliflozin 10 MGDRUG · verified · RxNorm: empagliflozin 10 MG
Sponsors & collaborators
Damanhour Universitylead sponsor
Tanta Universitycollaborator
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06313008 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.